Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors

Journal of Gastrointestinal Surgery

Volumn 6, Issue 5, 2002, Pages 664-670

  Schell, Scott R ^a,b   Camp, E Ramsay ^a   Caridi, James G ^a   Hawkins Jr , Irvin F ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carcinoid tumor; Combined modality therapy; Embolization; Gastrointestinal neoplasms; Liver neoplasms; Quality of life; Survival rate

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; GELFOAM; IODINATED POPPYSEED OIL; OCTREOTIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CONTRAST MEDIUM; GELATIN SPONGE; HEMOSTATIC AGENT;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASTHMA; CANCER PATIENT; CANCER SURGERY; CARCINOID; CARCINOID SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; ELECTROLYTE DISTURBANCE; EXPERIENCE; FEMALE; FLUSHING; FOLLOW UP; HEPATIC ARTERY; HUMAN; HYPERTENSION; LIVER METASTASIS; MALE; MEASUREMENT; PALLIATIVE THERAPY; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SYMPTOM; SYMPTOMATOLOGY; TUMOR BIOPSY; URINALYSIS; WHEEZING; CHEMOEMBOLIZATION; DRUG EFFECT; LIVER TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; SURVIVAL; URINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; GELATIN SPONGE, ABSORBABLE; HEMOSTATICS; HEPATIC ARTERY; HUMANS; HYDROXYINDOLEACETIC ACID; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; SURVIVAL ANALYSIS;

EID: 0036719833     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(02)00044-6     Document Type: Article

References (56)

1. Bax ND, Woods HF, Batchelor A, Jennings M. Clinical manifestations of carcinoid disease. World J Surg 1996; 20(2):142-146.
2. Norheim I, Oberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987;206(2):115-125.
3. Kloppel G, Heitz PU, Capella C, Solcia E. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 1996; 20(2):132-141.
4. Pasieka JL, McKinnon JG, Kinnear S, et al. Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: Symposium summary. Can J Surg 2001;44(1):25-32.
5. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg 1996;20(2):126-131.
6. Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumors: The place of somatostatin analogues. Digestion 1994;55(Suppl 3):107-113.
7. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996;39(2):279-283.
8. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg 1996:20(2)203-207.
9. Neary PC, Redmond PH, Houghton T, et al. carcinoid disease: Review of the literature. Dis Colon Rectum 1997; 40(3):349-362.
10. Krenning EP, Valkema R, Kooij PP, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethy triamine penta-acetic acid-D-Phe-1]-octreotide Ital J Gastroenterol Hepatol 1999;31(Suppl 2):S219-S223.
11. Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14(6)1829-1838.
12. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg 1996;20 (2):173-182.
13. Ahlman H, Westberg G, Wangberg B, et al. Treatment of liver metastases of carcinoid tumors. World J Surg 1996;20 (2):196-202.
14. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: Does intervention alter outcomes? J Am Coll Surg 2000;190(4):432-445.
15. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187(1):88-93.
16. Dominguez S, Denys A, Menu Y, Ruszniewski P. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol 1999;31(Suppl2):S213-S215.
17. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108(6):1091-1096.
18. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992;111(1):48-54.
19. Yao KK, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130(4):677-685.
20. Faiss S, Scherubl H, Riecken EO, Wiedenmann B. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 1996; 142:193-207.
21. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology-Group. Cancer 1996;77(2):402-408.
22. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2(4):327-334.
23. Oberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin - alone or in combination with 5-FU. Acta Oncol 1987;26(6):429-432.
24. Clouse ME, Perry L, Stuart K, Stokes KR. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994;55(Suppl 3):92-97.
25. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999;10(4): 397-403.
26. Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: Safety, complications, and when to worry. Radiographies 1999;19(2):399-414.
27. Lunderquist A, Ericsson M, Nobin A, Sanden G. Gelfoam powder embolization of the hepatic artery in liver metastases of carcinoid tumors. Radiologe 1982;22(2):65-70.
28. Marlink RG, Lokich JJ, Robins JR, Clouse ME. Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 1990;65(10):2227-2232.
29. Wangberg B, Geterud K, Nilsson O, et al. Embolisation therapy in the midgut carcinonid syndrome: Just tumour ischaemia? Acta Oncol 1993;32(2):251-256.
30. Winkelbauer FW, Niederle B, Pietschmann F, et al. Hepatic artery embolotherapy of hepatic metastases from carcinoid tumors: Value of using a mixture of cyanoacrylate and ethiodized oil. Am J Roentgenol 1995;165(2):323-327.
31. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001;95(1):8-12.
32. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000;62(Suppl 1):79-83.
33. Godwin JD, 2nd. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975;36(2):560-569.
34. Dousset B, Saint-Marc O, Pitre J, et al. Metastatic endocrine tumors: Medical treatment, surgical resection, or liver transplantation. World J Surg 1996;20(7):908-915.
35. Sweeney JF, Rosemurgy AS. Carcinoid tumors of the gut. Cancer Control 1997;4(1):18-24.
36. Pearson AS, Izzo F, Fleming RY, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999;178(6):592-599.
37. Curley SA, Izzo F, Delrio P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 1999;230(1):1-8.
38. Allison DJ, Modlin IM, Jenkins WJ. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet 1977;2:1323-1325.
39. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993;71(8):2624-2630.
40. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999;17(7):474-478.
41. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83(11):2293-2301.
42. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. AmJ Surg 1998;175(5):408-412.
43. Diamandidou E, Ajani JA, Yang DJ, et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. Am J Roentgenol 1998;170(2):339-344.
44. Wallace S, Ajani JA, Charnsangavej C, et al. Carcinoid tumors: Imaging procedures and interventional radiology. World J Surg 1996;20(2):147-156.
45. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120(4):302-309.
46. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993;189(2):541-547.
47. Stokes KR, Stuart K, Clouse ME. Hepatic arterial chemoembolization for metastatic endocrine tumors. J Vasc Interv Radiol 1993;4(3):341-345.
48. Carrasco CH, Charnsangavej C, Ajani J, et al. The carcinoid syndrome: Palliation by hepatic artery embolization. AmJ Roentgenol 1986;147(1):149-154.
49. Odurny A, Birch SJ. Hepatic arterial embolisation in patients with metastatic carcinoid tumours. Clin Radiol 1985;36 (6):597-602.
50. Stockmann F, Von Romatowski HJ, Reimold WV, et al. Hepatic artery embolization for treatment of endocrine gastrointestinal tumors with liver metastases. Z Gastroenterol 1984;22(11):652-660.
51. Maton PN, Camilleri M, Griffin G, et al. Role of hepatic arterial embolisation in the carcinoid syndrome. Br Med J (Clin Res Ed) 1983;287(6397):932-935.
52. Johnson G, Kalland T. Characterization of effector cells mediating the augmentation of spontaneous cell-mediated cytotoxicity induced by therapeutic infarction of human renal carcinomas. Urol Int 1984;39(4):236-240.
53. Bakke A, Gothlin JH, Haukaas SA, Kalland T. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res 1982;42(9):3880-3883.
54. Nakai T, Shimomura T, Hirokawa F. Spontaneous regression of recurrent hepatocellular carcinoma after TAE: Possible mechanisms of immune mediation. Int J Clin Oncol 2001;6(3):149-152.
55. Osada J, Pietruczuk M, Dabrowska M, et al. An assessment of lymphocytic population in peripheral blood of patients with renal cell carcinoma before and after embolization. Rocz Akad Med Bialymst 2000;45:228-239.
56. Wangberg B, Ahlman H, Tylen U, et al. Accumulation of natural killer cells after hepatic artery embolisation in the midgut carcinoid syndrome. Br J Cancer 1995;71(3):617-618.